CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
CytoDyn appointed Robert E. Hoffman as CEO effective October 20, 2026, replacing Dr. Jacob Lalezari, who led the company since November 2023. The transition is orderly: Hoffman joined in May 2025 as CFO and remains principal accounting officer, while Lalezari stays on as Head of Research and Translational Sciences focused on expanding leronlimab's solid-tumor oncology applications.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.